Søren B. van Witteloostuijn

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice

Jacob Jelsing, Niels Vrang, Søren B. van Witteloostuijn et al. · Journal of Endocrinology · 2012 · 48 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues

Esben M. Bech, Manuel C. Martos‐Maldonado, Pernille Wismann et al. · Journal of Medicinal Chemistry · 2017 · 38 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake

Louise S. Dalbøge, Søren L. Pedersen, Søren B. van Witteloostuijn et al. · Journal of Peptide Science · 2014 · 33 citations

Medicine, Pharmacokinetics, Pharmacology +13

Neoglycolipids for Prolonging the Effects of Peptides: Self-Assembling Glucagon-like Peptide 1 Analogues with Albumin Binding Properties and Potent in Vivo Efficacy

Søren B. van Witteloostuijn, Karin Mannerstedt, Pernille Wismann et al. · Molecular Pharmaceutics · 2016 · 31 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

GUB06‐046, a novel secretin/glucagon‐like peptide 1 co‐agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice

Søren B. van Witteloostuijn, Louise S. Dalbøge, Gitte Hansen et al. · Journal of Peptide Science · 2017 · 28 citations

Life Sciences, Endocrinology, Pharmacology +17